Results 101 to 110 of about 114,683,953 (299)
Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases
Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre +5 more
wiley +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley +1 more source
Sahel Medical Journal, 2019 Background: The use of botulinum toxin in neurology outpatient service is at its infancy in sub-Saharan Africa owing largely to the prohibitive cost and lack of requisite expertise in the use of the toxin. This leaves a huge gap in the treatment of focal
Frank Aiwansoba Imarhiagbe
doaj +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley +1 more source
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
Neurourology and Urodynamics, EarlyView.ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
, 2009 Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum. Although botulinum toxin is the cause of the disease botulism and can be used in a terrorist attack, there are also many other uses for botulinum toxin.
Moshayev, David
core +1 more source
Neurourology and Urodynamics, EarlyView.ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
Botulinum Toxin Type A for Pediatric Torticollis: A Review of Clinical Research
ToxinsPediatric torticollis, predominantly resulting from congenital muscular torticollis, is characterized by unilateral shortening of the sternocleidomastoid muscle, leading to head tilt and limited cervical mobility.
Na-Yoen Kwon +2 more
doaj +1 more source
A botulinum toxin farmakológiai felhasználásának lehetőségei
, 2017 A botulinum toxin egy rendkívül erélyes neurotoxin, melyet a Gram-pozítív anaerob spóraképző Clostridium botulinum termel. A toxinnak nyolc szerológiailag eltérő típusát különböztetjük meg az A, B, C (C1, C2), D, E, F, G és H, melyek eltérő antigén ...
Tolnai, Réka
core
Therapeutic Use of Botulinum Toxin in Neurology: a Literature Review
Botulinum toxin (BTX), a neurotoxin produced by Gram-positive Clostridium botulinum, is widely known for its broad application in aesthetic medicine, but it is also playing an increasingly important therapeutic role in neurology.
Natalia Skrzypska +5 more
core +1 more source